Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13-valent pneumococcal conjugate vaccine safety and immunogenicity study in Indian adults and children
2014-001174-34Phase 3
- Sponsor
- Pfizer
- Start
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Pfizer. Primary endpoint: Functional antibody titers.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2014-001174-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001174-34.